NasdaqCM - Nasdaq Real Time Price USD

Context Therapeutics Inc. (CNTX)

Compare

1.0800

-0.1300

(-10.74%)

At close: January 10 at 4:00:01 PM EST

1.0800

0.00

(0.00%)

After hours: 7:49:55 PM EST

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for so

GlobeNewswire 2 months ago

CNTX
-10.74%
Context Therapeutics to Participate in Upcoming Investor Conferences in November

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November: Guggenheim Global Healthcare Conference: Fireside chat on Monday, November 11, 2024, at 3:00 p.m. ET in Boston, MA. UBS Global Healthcare Conference: Fireside chat on Wednesday, November 13, 2024, at 11:45 a.m. P

GlobeNewswire 2 months ago

CNTX
-10.74%
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details:

GlobeNewswire 2 months ago

CNTX
-10.74%
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developme

GlobeNewswire 3 months ago

BCAB

CNTX
-10.74%
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Context Therapeutics...

Simply Wall St. 3 months ago

CNTX
-10.74%
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Zacks 3 months ago

CNTX
-10.74%
COLL
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategyPHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. “Karen and Luke’s vast e

GlobeNewswire 4 months ago

CNTX
-10.74%
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlight

GlobeNewswire 5 months ago

CNTX
-10.74%
Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms

Key Insights Context Therapeutics' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. 5 months ago

CNTX
-10.74%
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company’s two clinical-stage T cell engaging assets to treat solid tumors PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical

GlobeNewswire 5 months ago

CNTX
-10.74%
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunoth

GlobeNewswire 5 months ago

CNTX
-10.74%
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?

Here is how CareCloud, Inc. (CCLD) and Context Therapeutics Inc. (CNTX) have performed compared to their sector so far this year.

Zacks 6 months ago

CCLD

CNTX
-10.74%
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight

Hypergrowth stocks are the holy grail of traders and growth investors. These stocks can multiply a small position by two, five, 10 times, or more. In many cases, analysts like to project what stocks they believe can deliver this kind of market-beating performance in the future. However, this article analyzes three stocks that have posted a 100% or higher increase in share price over the last 12 months. Past results don’t always equate to future performance. And it’s fair to note that many hyperg

InvestorPlace 7 months ago

ACMR

NVDA

TDW-WT
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:PIPR) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. Piper Sandler may be the best bet for investors especially when you see

InvestorPlace 7 months ago

CNTX
-10.74%
RVNC

ABBV
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

Does Context Therapeutics Inc. (CNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 7 months ago

CNTX
-10.74%
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 7 months ago

CNTX
-10.74%
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights. “We believe Context has had a great

GlobeNewswire 7 months ago

CNTX
-10.74%
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T

GlobeNewswire 8 months ago

CNTX
-10.74%
Context Therapeutics Announces $100 Million Private Placement

Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expec

GlobeNewswire 8 months ago

CNTX
-10.74%
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76. The IND supports the initiation of a Ph

GlobeNewswire 9 months ago

CNTX
-10.74%

Performance Overview

Return	CNTX	S&P 500
YTD	+1.89%	-1.35%
1-Year	-11.48%	+22.51%
3-Year	-57.31%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Context Therapeutics Inc. (CNTX)

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?

Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight

The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Announces $100 Million Private Placement

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Performance Overview